Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Completion of Acquisition or Disposition of Assets
Item 2.01 Completion of Acquisition or Disposition of Assets.

Following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, on March 30, 2017, Sarepta Therapeutics Inc. (the “Company”) completed its sale to a subsidiary of Gilead Sciences, Inc. (“Gilead”) of its Rare Pediatric Disease Priority Review Voucher (the “Asset Sale”), which was awarded to the Company by the U.S. Food and Drug Administration to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. The Asset Sale was to the terms of an Asset Purchase Agreement, dated February 20, 2017 (the “Agreement”), previously disclosed by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2017. to the Agreement, a subsidiary of Gilead paid the Company $125 million upon the closing of the Asset Sale.

About Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Recent Trading Information

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) closed its last trading session 00.00 at 29.01 with 1,306,031 shares trading hands.